Animal Health Earnings Week: Elanco Rises, Zoetis Cuts Guidance, Merck Delivers — and IDEXX Steals the Show

The week of 3–7 August 2026 delivered the animal health sector’s most consequential earnings sequence of the year: Zoetis beat EPS estimates but issued a material guidance cut that triggered another sell-off, Elanco raised guidance for the third consecutive quarter and jumped 5.86% in premarket before partially retracing on profit-taking, Merck Animal Health delivered 8% revenue growth, and IDEXX quietly beat estimates and raised its own full-year outlook to end the week as the sector’s best performer.

Elanco’s shares jumped 5.86% in premarket trading to $27.10 on Wednesday, approaching its 52-week high of $27.72, as investors responded positively to broad-based growth and an improved financial outlook. Revenue of $1.37 billion , up 10% reported and 8% organically , beat consensus, with Zenrelia achieving blockbuster status, Credelio Quattro penetrating over 50% of US clinics, and Befrena demand running at twice initial expectations. Full-year revenue guidance was raised to $5.09–$5.14 billion and adjusted EPS guidance lifted to $1.10–$1.16, a 20% year-on-year increase at the midpoint. The consensus analyst price target stood at $30.07 ahead of results. However, the stock gave back gains through the week, closing around $25.20 on Friday as profit-takers locked in returns on a stock up 83% over twelve months. The quarter delivered 8% organic revenue and 8.6% operating margins. The Q3 EBITDA guidance of $200–$215 million disappointed some analysts, with Stifel describing the results as having “a few blemishes” though maintaining its Buy rating.

Zoetis reported Q2 revenue of $2.5 billion , flat year-on-year , with adjusted EPS of $1.87, a marginal beat against the $1.86 consensus. But full-year revenue guidance was cut to $9.12–$9.32 billion from $9.68–$9.96 billion, with adjusted EPS lowered to $6.15–$6.25 against a prior $6.85–$7.00. US companion animal sales fell 11% as lower clinic visits, pet owner price sensitivity and intensifying competition in dermatology and parasiticides continued to bite. ZTS fell 3.2% in premarket on Thursday. UBS cut its target to $85 from $99 maintaining Neutral; Morgan Stanley lowered to $99 from $115 retaining Overweight. The stock closed the week around $75–77, near its 52-week low of $72.38.

Merck Animal Health contributed $1.78 billion in Q2 revenue, up 8% year-on-year, with the division now tracking toward a full-year total exceeding its $6.4 billion 2025 result and representing approximately 10.7% of Merck’s $16.6 billion group quarter.

Among the wider sector, IDEXX was the standout , reporting Q2 EPS of $4.07 against a $3.93 consensus and raising full-year EPS guidance to $14.69–$14.94, with shares rising approximately 5% on the week. Phibro traded around $37, Virbac at €317, Vetoquinol near €72 , close to its 52-week low , while Eco Animal Health and Ourofino were broadly quiet in thin trading.